Dung-Tsa Chen
Overview
Explore the profile of Dung-Tsa Chen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
128
Citations
3082
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
31.
Sahebjam S, Forsyth P, Tran N, Arrington J, MacAulay R, Etame A, et al.
Neuro Oncol
. 2020 Nov;
23(4):677-686.
PMID: 33173935
Background: Radiotherapy may synergize with programmed cell death 1 (PD1)/PD1 ligand (PD-L1) blockade. The purpose of this study was to determine the recommended phase II dose, safety/tolerability, and preliminary efficacy...
32.
Beato F, Reveron D, Dezsi K, Ortiz A, Johnson J, Chen D, et al.
Lab Invest
. 2020 Oct;
101(2):204-217.
PMID: 33037322
Pancreatic cancer (PaCa) is the third leading cause of cancer-related deaths in the United States. There is an unmet need to develop strategies to detect PaCa at an early, operable...
33.
Kim R, Tan E, Wang E, Mahipal A, Chen D, Cao B, et al.
Oncologist
. 2020 Aug;
25(12):e1893-e1899.
PMID: 32776632
Lessons Learned: The combination of trametinib and sorafenib has an acceptable safety profile, albeit at doses lower than approved for monotherapy. Maximum tolerated dose is trametinib 1.5 mg daily and...
34.
Huynh T, Ali K, Vyas S, Dezsi K, Strickland D, Basinski T, et al.
Pancreatology
. 2020 Mar;
20(3):448-453.
PMID: 32113936
Background: Intraductal papillary mucinous neoplasms (IPMNs) are pre-malignant pancreatic cysts detected by imaging. Cyst size is one of many features evaluated on computed tomography (CT), magnetic resonance imaging (MRI), or...
35.
Chen D, Schell M, Fulp W, Pettersson F, Kim S, Gray J, et al.
Transl Cancer Res
. 2019 Aug;
8(Suppl 4):S404-S420.
PMID: 31456910
Background: Bayesian predictive probability design, with a binary endpoint, is gaining attention for the phase II trial due to its innovative strategy. To make the Bayesian design more accessible, we...
36.
Sun J, Chen D, Li J, Sun W, Yoder S, Mesa T, et al.
J Surg Res
. 2019 Aug;
245:153-162.
PMID: 31419640
Background: Breast cancer (BC) risk assessment models are statistical estimates based on patient characteristics. We developed a gene expression assay to assess BC risk using benign breast biopsy tissue. Methods:...
37.
Gray J, Saltos A, Tanvetyanon T, Haura E, Creelan B, Antonia S, et al.
Clin Cancer Res
. 2019 Aug;
25(22):6623-6632.
PMID: 31409616
Purpose: Histone deacetylase inhibitors (HDACi) enhance tumor immunogenicity through several mechanisms and may improve response to immune checkpoint inhibitors (ICIs). In a phase I/Ib trial, we tested the oral HDACi...
38.
Permuth J, Clark Daly A, Jeong D, Choi J, Cameron M, Chen D, et al.
Cancer Med
. 2019 May;
8(6):3314-3324.
PMID: 31074202
Pancreatic cancer (PC) is characterized by racial/ethnic disparities and the debilitating muscle-wasting condition, cancer cachexia. Florida ranks second in the number of PC deaths and has a large and understudied...
39.
Chiappori A, Williams C, Gray J, Tanvetyanon T, Haura E, Creelan B, et al.
Cancer Immunol Immunother
. 2018 Dec;
68(3):517-527.
PMID: 30591959
Small cell lung cancer TP53 mutations lead to expression of tumor antigens that elicits specific cytotoxic T-cell immune responses. In this phase II study, dendritic cells transfected with wild-type TP53...
40.
Luu C, Thapa R, Rose T, Woo K, Jeong D, Thomas K, et al.
Int J Surg
. 2018 Sep;
58:46-49.
PMID: 30218781
Background: Nonalcoholic fatty liver disease (NAFLD) following pancreatectomy is a potential cause of long term morbidity in patients undergoing pancreatic resection with curative intent. Prior studies have reported an incidence...